Original articleOutcomes with As-Needed Ranibizumab after Initial Monthly Therapy: Long-Term Outcomes of the Phase III RIDE and RISE Trials
Abbreviations and Acronyms
Cited by (0)
∗Supplemental material is available at www.aaojournal.org.
Financial Disclosure(s): The author(s) have made the following disclosure(s): D.S.B.: Consultant − Alcon, Allergan, Eyetech, Genentech, Inc., Novartis/QLT, Neurotech, Pfizer, Regeneron, Allegro, Ohr; Speakers Bureau – Alcon, Allergan, Genentech, Inc., Pfizer; Clinical Research Projects: Alcon, Allergan, Genentech, Inc., Pfizer, Regeneron.
Q.D.N.: Research Grants − Genentech, Inc., Regeneron, Pfizer; Advisory boards: Genentech, Inc., AbbVie, Regeneron; Consultant: Santen Pharmaceuticals, Bausch & Lomb.
D.M.B.: Research Grants − Genentech, Inc., Regeneron, Novartis, Alcon, Allergan, Alimera Sciences, Eli Lilly, Molecular Partners, Ophthotech, Abbott, Schering Plough, Othera Pharmaceuticals, Paloma Pharmaceuticals, Neurotech, TargeGen, Sirion Therapeutics, Inc., Jerini AG; Consultant: Genentech, Inc., Regeneron, Allergan, Alcon, Molecular Partners, Novartis, Oraya Therapeutics, Paloma Pharmaceuticals, Steba Biotech; Speakers Bureau – Genentech, Inc.
K.B.: Employee − Genentech, holds Roche stock/stock options.
J.S.E.: Employee − Genentech, holds Roche stock/stock options.
Supported by Genentech, Inc. Support for third-party writing assistance was provided by Genentech, Inc. The sponsor participated in the design and conduct of the study; collection, management, analysis, and interpretation of the data; and preparation and review of the manuscript.
Author Contributions:
Conception and design: Boyer, Nguyen, Brown, Basu, Ehrlich
Data collection: Boyer, Nguyen, Brown, Basu, Ehrlich
Analysis and interpretation: Boyer, Nguyen, Brown, Basu, Ehrlich
Obtained funding: Not applicable
Overall responsibility: Boyer, Nguyen, Brown, Basu, Ehrlich
- ∗
The RIDE and RISE Research Group is listed in the Appendix (available at www.aaojournal.org).